An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia
NCT ID: NCT01105494
Last Updated: 2012-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6000 participants
OBSERVATIONAL
2008-12-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
NCT00321919
A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia
NCT02569515
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
NCT00413101
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
NCT00440063
Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant
NCT00815867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
epoetin beta [NeoRecormon]
As prescribed by physician
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Dialysis patients with chronic renal anemia
* Written informed consent
Exclusion Criteria
* Severe neuropsychological disorder
* Diabetic patients with serious complications
This trial is being conducted in Morocco.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Casablanca, , Morocco
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML21906
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.